Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 YearsNarjust Duma, Alex A. Adjei, Yucai Wang et al.|Journal of Oncology Practice|2017Cited by 447
<sup>Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal CancerJeremy Jones, Axel Grothey, Lindsay A. Renfro et al.|Journal of Clinical Oncology|2017Cited by 357
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Andrea Cercek, Salvatore Siena et al.|The Lancet Oncology|2023Cited by 244